drugset

drugset / Trial / NCT01085266

An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease

NCT01085266 ↗

Phase 3 Terminated 362 enrolled Medivation, Inc. Pfizer · collab

NaSingle-groupOpen-labelTreatment

Summary

An open-label extension study of the HORIZON protocol evaluating the safety of dimebon (latrepirdine)in subjects with Huntington disease.

Timeline

Start: 2010-02
Primary completion: 2011-06
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Latrepirdine	Small molecule	20 mg	Oral

Indications